Opdivo + Cabometyx receives FDA approval for advanced renal cell carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has approved a combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) as first-line treatment for patients with advanced renal cell carcinoma.

Opdivo is sponsored by Bristol-Myers Squibb and Cabometyx is sponsored by Exelixis.

Efficacy was evaluated in CHECKMATE-9ER (NCT03141177), a randomized, open-label trial in patients with previously untreated advanced RCC. Patients were randomized to receive either nivolumab 240 mg over 30 minutes every two weeks in combination with cabozantinib 40 mg orally once daily (n=323) or sunitinib 50 mg orally daily for the first four weeks of a six-week cycle (four weeks on treatment followed by two weeks off) (n=328).

The trial demonstrated a statistically significant improvement in progression-free survival, overall survival, and confirmed overall response rate for patients treated with Opdivo plus Cabometyx compared with those who received sunitinib. Median PFS per blinded independent central review (BICR) was 16.6 months versus 8.3 months; HR 0.51 (95% CI: 0.41, 0.64).

Median OS was not reached in either arm; HR 0.60 (95% CI: 0.40, 0.89). Confirmed ORR per BICR was 55.7% and 27.1% in the nivolumab plus cabozantinib and sunitinib arms, respectively.

Table of Contents

YOU MAY BE INTERESTED IN

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login